387 related articles for article (PubMed ID: 25791825)
1. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.
Meyerhoff RR; Yang CF; Speicher PJ; Gulack BC; Hartwig MG; D'Amico TA; Harpole DH; Berry MF
J Surg Res; 2015 Jun; 196(1):23-32. PubMed ID: 25791825
[TBL] [Abstract][Full Text] [Related]
2. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
Verma V; Ahern CA; Berlind CG; Lindsay WD; Shabason J; Sharma S; Culligan MJ; Grover S; Friedberg JS; Simone CB
Clin Lung Cancer; 2018 Nov; 19(6):e901-e912. PubMed ID: 30224273
[TBL] [Abstract][Full Text] [Related]
3. An Investigation of Cancer-Directed Surgery for Different Histologic Subtypes of Malignant Pleural Mesothelioma.
Mansur A; Potter AL; Zurovec AJ; Nathamuni KV; Meyerhoff RR; Berry MF; Kang A; Jeffrey Yang CF
Chest; 2023 May; 163(5):1292-1303. PubMed ID: 36574925
[TBL] [Abstract][Full Text] [Related]
4. Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma?
Kim S; Bull DA; Garland L; Khalpey Z; Stea B; Yi S; Hsu CC
Ann Thorac Surg; 2019 Jan; 107(1):194-201. PubMed ID: 30278171
[TBL] [Abstract][Full Text] [Related]
5. Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.
Vigneswaran WT; Kircheva DY; Ananthanarayanan V; Watson S; Arif Q; Celauro AD; Kindler HL; Husain AN
Ann Thorac Surg; 2017 Mar; 103(3):962-966. PubMed ID: 27765170
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?
Balduyck B; Trousse D; Nakas A; Martin-Ucar AE; Edwards J; Waller DA
Ann Thorac Surg; 2010 Mar; 89(3):907-11. PubMed ID: 20172152
[TBL] [Abstract][Full Text] [Related]
7. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
[TBL] [Abstract][Full Text] [Related]
8. Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients.
Taioli E; Wolf AS; Camacho-Rivera M; Kaufman A; Lee DS; Nicastri D; Rosenzweig K; Flores RM
PLoS One; 2015; 10(12):e0145039. PubMed ID: 26660351
[TBL] [Abstract][Full Text] [Related]
9. Initial analysis of the international association for the study of lung cancer mesothelioma database.
Rusch VW; Giroux D; Kennedy C; Ruffini E; Cangir AK; Rice D; Pass H; Asamura H; Waller D; Edwards J; Weder W; Hoffmann H; van Meerbeeck JP;
J Thorac Oncol; 2012 Nov; 7(11):1631-9. PubMed ID: 23070243
[TBL] [Abstract][Full Text] [Related]
10. The new case for cervical mediastinoscopy in selection for radical surgery for malignant pleural mesothelioma.
Nakas A; Waller D; Lau K; Richards C; Muller S
Eur J Cardiothorac Surg; 2012 Jul; 42(1):72-6; discussion 76. PubMed ID: 22290929
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.
Chirieac LR; Hung YP; Foo WC; Hofer MD; VanderLaan PA; Richards WG; Sugarbaker DJ; Bueno R
Cancer; 2019 Dec; 125(23):4164-4171. PubMed ID: 31390057
[TBL] [Abstract][Full Text] [Related]
12. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
Linton A; Pavlakis N; O'Connell R; Soeberg M; Kao S; Clarke S; Vardy J; van Zandwijk N
Br J Cancer; 2014 Oct; 111(9):1860-9. PubMed ID: 25188323
[TBL] [Abstract][Full Text] [Related]
14. Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma.
Yang CJ; Yan BW; Meyerhoff RR; Saud SM; Gulack BC; Speicher PJ; Hartwig MG; D'Amico TA; Harpole DH; Berry MF
Clin Lung Cancer; 2016 Sep; 17(5):419-426. PubMed ID: 27236386
[TBL] [Abstract][Full Text] [Related]
15. Reproducibility of histological subtyping of malignant pleural mesothelioma.
Brčić L; Jakopović M; Brčić I; Klarić V; Milošević M; Sepac A; Samaržija M; Seiwerth S
Virchows Arch; 2014 Dec; 465(6):679-85. PubMed ID: 25300229
[TBL] [Abstract][Full Text] [Related]
16. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
17. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
Kircheva DY; Husain AN; Watson S; Kindler HL; Durkin A; Vigneswaran WT
Eur J Cardiothorac Surg; 2016 Jun; 49(6):1642-7. PubMed ID: 26802143
[TBL] [Abstract][Full Text] [Related]
18. High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology.
Kadota K; Kachala SS; Nitadori J; Suzuki K; Dunphy MP; Sima CS; Travis WD; Rusch VW; Adusumilli PS
J Thorac Oncol; 2012 Jul; 7(7):1192-7. PubMed ID: 22617244
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.
Matsumoto S; Nabeshima K; Hamasaki M; Shibuta T; Umemura T
Med Oncol; 2014 Dec; 31(12):303. PubMed ID: 25358615
[TBL] [Abstract][Full Text] [Related]
20. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
